Cliff Asness’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $76.9M | Sell |
4,325,689
-2,107,423
| -33% | -$39.9M | 0.03% | 681 |
|
|
2026
Q1 | $139M | Sell |
6,433,112
-1,363,423
| -17% | -$26.4M | 0.06% | 417 |
|
|
2025
Q4 | $168M | Buy |
7,796,535
+6,390,860
| +455% | +$135M | 0.09% | 308 |
|
|
2025
Q3 | $26.4M | Buy |
1,405,675
+1,279,696
| +1,016% | +$22.8M | 0.02% | 770 |
|
|
2025
Q2 | $2.15M | Buy |
125,979
+120,594
| +2,239% | +$5.14M | ﹤0.01% | 1730 |
|
|
2025
Q1 | $344K | Buy |
5,385
+3,671
| +214% | +$386K | ﹤0.01% | 2628 |
|
|
2024
Q4 | $208K | Buy |
+1,714
| New | +$210K | ﹤0.01% | 2657 |
|
|
2023
Q4 | – | Sell |
-8,422
| Closed | -$1.02M | – | 2439 |
|
|
2023
Q3 | $1.02M | Sell |
8,422
-1,299
| -13% | -$147K | ﹤0.01% | 1590 |
|
|
2023
Q2 | $1.11M | Buy |
9,721
+1,829
| +23% | +$236K | ﹤0.01% | 1508 |
|
|
2023
Q1 | $1.09M | Buy |
7,892
+5,066
| +179% | +$657K | ﹤0.01% | 1509 |
|
|
2022
Q4 | $366K | Buy |
2,826
+95
| +3% | +$11K | ﹤0.01% | 1918 |
|
|
2022
Q3 | $302K | Buy |
+2,731
| New | +$275K | ﹤0.01% | 1943 |
|
|
2021
Q1 | – | Sell |
-4,834
| Closed | -$824K | – | 2263 |
|
|
2020
Q4 | $824K | Sell |
4,834
-180
| -4% | -$26.7K | ﹤0.01% | 1588 |
|
|
2020
Q3 | $704K | Buy |
5,014
+3,158
| +170% | +$480K | ﹤0.01% | 1587 |
|
|
2020
Q2 | $298K | Sell |
1,856
-2,836
| -60% | -$386K | ﹤0.01% | 1889 |
|
|
2020
Q1 | $459K | Sell |
4,692
-1,190
| -20% | -$136K | ﹤0.01% | 1614 |
|
|
2019
Q4 | $759K | Sell |
5,882
-1,754
| -23% | -$177K | ﹤0.01% | 1605 |
|
|
2019
Q3 | $575K | Sell |
7,636
-8,784
| -53% | -$1.04M | ﹤0.01% | 1710 |
|
|
2019
Q2 | $2.5M | Sell |
16,420
-4,957
| -23% | -$602K | ﹤0.01% | 1194 |
|
|
2019
Q1 | $2.55M | Buy |
21,377
+1,196
| +6% | +$154K | ﹤0.01% | 1222 |
|
|
2018
Q4 | $2.2M | Sell |
20,181
-5,437
| -21% | -$680K | ﹤0.01% | 1213 |
|
|
2018
Q3 | $4.14M | Sell |
25,618
-45,231
| -64% | -$6.18M | ﹤0.01% | 1079 |
|
|
2018
Q2 | $9.37M | Sell |
70,849
-17,427
| -20% | -$1.64M | 0.01% | 809 |
|
|
2018
Q1 | $6.54M | Buy |
88,276
+16,176
| +22% | +$1.08M | 0.01% | 902 |
|
|
2017
Q4 | $4.01M | Sell |
72,100
-9,368
| -11% | -$496K | ﹤0.01% | 1113 |
|
|
2017
Q3 | $3.69M | Buy |
81,468
+28,600
| +54% | +$1.14M | ﹤0.01% | 1148 |
|
|
2017
Q2 | $1.78M | Buy |
52,868
+501
| +1% | +$16.3K | ﹤0.01% | 1435 |
|
|
2017
Q1 | $1.55M | Buy |
52,367
+10,648
| +26% | +$330K | ﹤0.01% | 1496 |
|
|
2016
Q4 | $1.14M | Buy |
41,719
+36,738
| +738% | +$1.48M | ﹤0.01% | 1660 |
|
|
2016
Q3 | $306K | Buy |
+4,981
| New | +$151K | ﹤0.01% | 2075 |
|
|
2016
Q2 | – | Sell |
-23,268
| Closed | -$454K | – | 2256 |
|
|
2016
Q1 | $454K | Sell |
23,268
-8,932
| -28% | -$156K | ﹤0.01% | 1873 |
|
|
2015
Q4 | $1.24M | Buy |
32,200
+15,125
| +89% | +$490K | ﹤0.01% | 1479 |
|
|
2015
Q3 | $548K | Buy |
+17,075
| New | +$579K | ﹤0.01% | 1680 |
|
|
2014
Q1 | – | Sell |
-32,000
| Closed | -$652K | – | 2623 |
|
|
2013
Q4 | $652K | Sell |
32,000
-14,488
| -31% | -$431K | ﹤0.01% | 1932 |
|
|
2013
Q3 | $2.2M | Buy |
46,488
+16,115
| +53% | +$621K | 0.01% | 1234 |
|
|
2013
Q2 | $1.16M | Buy |
+30,373
| New | +$1.09M | ﹤0.01% | 1498 |
|
Other funds holding SRPT
EAM
Cliff Asness's SRPT Position: Q2 2026 in Review
Cliff Asness reduced its Sarepta Therapeutics (SRPT) stake by 33% in Q2 2026, selling an estimated $39.9M and leaving 4,325,689 shares worth $76.9M. The position accounts for 0.03% of the portfolio, ranked #681.
Cliff Asness first reported a position in SRPT in Q2 2013 and has held it in 36 quarters since. The position peaked at $168M in Q4 2025. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Cliff Asness held 4,325,689 shares of Sarepta Therapeutics worth $76.9M as of Q2 2026.
- Cliff Asness sold 2,107,423 Sarepta Therapeutics shares in Q2 2026, an estimated $39.9M.
- Sarepta Therapeutics made up 0.03% of Cliff Asness's portfolio in Q2 2026, its #681 holding.
- Cliff Asness first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 36 quarters since.
- Cliff Asness's Sarepta Therapeutics position peaked at $168M in Q4 2025.
- 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.